News & Updates

For adults with type 2 diabetes (T2D) and obesity, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide provides substantial protection against dementia, stroke, and death, according to a large retrospective cohort study.

The use of SGLT-2 inhibitors does not appear to pose an elevated risk of urinary tract infection (UTI) among male veterans with type 2 diabetes (T2D), a recent study has shown.

Compared with using SGLT-2 inhibitors, treatment with GLP-1 receptor agonists (RAs) may increase the risk for gastroesophageal reflux disease (GERD) and its complications in patients with type 2 diabetes (T2D), a recent study has shown.

Further stratification of BMI categories by waist circumference (WC) thresholds can improve prediction of mortality risk among postmenopausal women, suggests a recent study, noting the association of larger WC with greater mortality.

Several factors, including BMI and Charlson Comorbidity Index (CCI), can help predict treatment response among patients with psoriasis, suggests a study.

The addition of once-weekly semaglutide to an automated insulin delivery (AID) system leads to significantly improved time in range (TIR) and reduced body weight in adults with type 1 diabetes (T1D) and obesity compared with AID alone, according to the ADJUST-T1D* trial presented at ADA 2025. 

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.